Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes

Subhamoy Das, Anthony J. Monteforte, Gunjan Singh, Marjan Majid, Michael Sherman, Andrew K. Dunn, Aaron B. Baker

    Research output: Contribution to journalArticle

    11 Scopus citations


    Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.

    Original languageEnglish (US)
    JournalAdvanced healthcare materials
    StateAccepted/In press - 2016



    • Fibroblast growth factor-2 (FGF-2)
    • Ischemia
    • Peripheral vascular diseases
    • Syndecan-4
    • Therapeutic angiogenesis

    ASJC Scopus subject areas

    • Biomedical Engineering
    • Biomaterials
    • Pharmaceutical Science

    Cite this